Mechanisms of thrombosis related to hormone therapy
- 31 December 2009
- journal article
- Published by Elsevier BV in Thrombosis Research
- Vol. 123, S70-S73
- https://doi.org/10.1016/s0049-3848(09)70015-5
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk
This publication has 22 references indexed in Scilit:
- Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markersJournal of Thrombosis and Haemostasis, 2008
- Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitorJournal of Thrombosis and Haemostasis, 2008
- Inhibitors and activation markers of the haemostatic system during hormone therapy: A comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestoneThrombosis and Haemostasis, 2008
- Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysisThrombosis Research, 2007
- Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulationMaturitas, 2006
- Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart diseaseJournal of Internal Medicine, 2004
- Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosisBlood, 2003
- Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over studyThe Lancet, 1999
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second‐ and third‐generation oral contraceptivesBritish Journal of Haematology, 1997